Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Taltz (ixekizumab) is indicated for the treatment of patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, the treatment of adults with active psoriatic arthritis, the treatment of adults with active ankylosing spondylitis, and the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.
• This summary is based on the review of 37 systematic review(s)/meta-analysis(es). ^[1-37]
• Ixekizumab showed the highest rate of complete resolution in Nail Psoriasis (NP) compared to adalimumab, brodalumab, guselkumab, infliximab, and ustekinumab.
• For Axial Spondylarthritis (axSpA), ixekizumab significantly improved ASAS40, ASDAS, and SPRACC scores compared to placebo.
• In patients with moderate-to-severe psoriasis, ixekizumab was highly effective in achieving PASI 90, PASI 75, and PASI 100, both in short-term (10-16 weeks) and long-term (around 1 year) treatments.
• Ixekizumab demonstrated high efficacy in achieving a 75% improvement in PASI in pediatric patients with moderate-to-severe psoriasis.
• Ixekizumab was associated with a significant increase in the risk of non-serious adverse events (NSAEs) in patients with axial spondylarthritis, although no significant increase in serious adverse events (SAEs) was observed compared to placebo.
• In studies involving patients with psoriasis, ixekizumab did not show a significant difference in SAEs compared to placebo, but higher rates of injection site reactions were reported.
• The safety profile of ixekizumab in patients with psoriatic arthritis was comparable to other biologics, with no significant differences in SAEs.
• Studies included pediatric patients with moderate-to-severe psoriasis, patients with Pityriasis Rubra Pilaris (PRP), patients with Axial Spondylarthritis (axSpA), and patients with Psoriatic Arthritis (PsA). Significant findings include high efficacy in achieving PASI75 in pediatric psoriasis, substantial therapeutic impact on PRP, notable improvements in axSpA efficacy outcomes, and effective clinical responses in PsA, with a comparable safety profile across these populations.